

JFW

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/785,215	
	Filing Date	February 23, 2004	
	First Named Inventor	Craig P. Roberts et al.	
	Art Unit	1614	
	Examiner Name	Unknown	
Total Number of Pages in This Submission	6	Attorney Docket Number	51283-00002

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Substitute Form PTO-1449 (3 pgs) and Non-US Patent References listed on substitute for PTO-1449 (35)
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Michelle S. Glasky Preston Gates & Ellis, LLP Reg. No.: 54,124
Signature	<i>Michelle Glasky</i>
Date	3/1/05

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Dulcie Donoso Fontt		
Signature	<i>Dulcie Donoso Fontt</i>	Date	3/1/05

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



## PATENT

### CERTIFICATE OF MAILING

I hereby certify that on March 1, 2005, this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage to in an envelope addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Dulcie Donoso Fontt

Inventor: Roberts, Craig P. et al.  
Serial No.: 10/785,215  
Filing Date: February 23, 2004  
Title: PLASMA DETOXIFICATION  
SYSTEM AND METHODS OF  
USE

Examiner: Unknown  
Group Art Unit: 1614  
Atty Docket No.: 51283-00002

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

### INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, and in accordance with the provisions in the Manual of Patent Examining Procedure §§609 and 707.05(b), enclosed is a copy of the substitute for FORM PTO-1449 listing the references that are known to applicant. Applicants enclose copies of each of the listed references which are not U.S. patents.

This art is being filed for consideration in compliance with § 1.97 within the following time period:

37 C.F.R. § 1.97 (b) This information disclosure statement is being filed by the applicant for consideration and entry before the mailing of a first office action on the merits.

The submission of the above-described documents does not constitute an admission nor should it be construed as a representation that a search has been made,

construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b).


Applicant reserves the right to antedate or otherwise remove the documents as references.

It is respectfully requested that the listed references be considered in the examination of this application and identified on the list of references cited on the patent issuing for this application. Applicant also requests that an initialed copy of the substitute for FORM PTO-1449 be entered in the application file and returned to applicant with the next communication from the Office in accordance with MPEP § 609.


The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application. Applicant believes that no fee is due with this communication; however, if the Commissioner deems a fee is due, the Director is hereby authorized to charge any fees to Deposit Account No. 50-1329. A duplicate copy of this sheet is enclosed.

Respectfully submitted,  
PRESTON GATES & ELLIS LLP

Dated: 3/1/05

  
Michelle S. Glasky  
Registration No. 54,124

PRESTON GATES & ELLIS LLP  
1900 Main Street, Suite 600  
Irvine, California 92614-7319  
Telephone: (949) 253-0900  
Facsimile: (949) 253-0902  
**Customer Number: 45,200**



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/785,215
				Filing Date	02/23/2004
				First Named Inventor	Craig P. Roberts
				Group Art Unit	1614
				Examiner Name	Unassigned
Sheet	1	of	3	Attorney Docket Number	51283-00002

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)				
	AA	US	-4,127,481	11/28/1978	Malchesky et al.	
	AB	US	-4,231,871	11/04/1980	Lipps et al.	
	AC	US	-4,267,047	05/12/1981	Henne et al.	
	AD	US	-4,269,708	05/26/1981	Bonomini et al.	
	AE	US	-4,617,115	10/14/1986	Vantard	
	AF	US	-4,747,822	05/31/1988	Peabody	
	AG	US	-4,769,037	09/06/1988	Midcalf	
	AH	US	-5,015,388	05/14/1991	Pusineri et al.	
	AI	US	-5,571,418	11/05/1996	Lee et al.	
	AJ	US	-6,008,049	12/28/1999	Naughton et al.	
	AK	US	-6,186,146	02/13/2001	Glickman	
	AL	US	-6,287,516	09/11/2001	Matson et al.	
	AM	US	-6,372,482	04/16/2002	Mitrani	
	AN	US	-2001/0051106	12/13/2001	Matson et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Date of Publications of Cited Documents MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				
	AP	WO	00/02603		01/20/2000	Bioscience Research Associates		
	AQ	WO	03/009885		06/02/2003	Immunocept LLC		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.4. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application or to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, Patent and Trademark Office, US Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/785,215
Filing Date	02/23/2004
First Named Inventor	Craig P. Roberts
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	51283-00002

Sheet

2

of

3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AR	Anand A.C., Nightingale P., Neuberger J.M., Early indicators of prognosis in fulminant hepatic failure: an assessment of the King's criteria, J Hepatology, 1997; 26:62-68.	
	AS	Ash S.R., Treatment of Acute Hepatic Failure with Encephalopathy: A review, Int. J. Artif Organs, 1991; 14:191-195.	
	AT	Awad S.S. et al., A novel stable reproducible model of hepatic failure canines, J. Surg. Res., 2000; 94:167-71.	
	AU	Bende S. et al., Elimination of endotoxin from the blood by extracorporeal activated charcoal hemoperfusion in experimental canine endotoxin shock, Circulatory Shock, 1986; 19:239-244.	
	AV	Ellis A.J. et al., Temporary extracorporeal liver support for several acute alcoholic hepatitis using the BioLogic-DT, Int. J. Artif. Organs, 1999; 22:27-34.	
	AW	Falhenhagen D. et al., Fracionated plasma separation and adsorption system: A novel system for blood purification to remove albumin bound substances, Artif. Organs, 1999; 23:81-6.	
	AX	Hughes R.D. and Williams R., Use of sorbent columns and haemofiltration in fulminant hepatic failure, Blood Purif., 1993; 11:163-9.	
	AY	Hughes R.D. et al., Artificial liver support in acute liver failure: a review of studies at King's, Artif. Organs 1992; 16:167-70.	
	AZ	Hughes R.D., In-vitro blood compatibility studies on a new polymer-coated charcoal for haemoperfusion, The Inter'l Journal of Artificial Organs, 1980; 3(5): 277-279.	
	BA	Hughes R.D., Platelet function during haemoperfusion in acute liver failure, The Inter'l Journal of Artificial Organs, 1980; 3(1):30-34.	
	BB	Kellum J.A. and Dishart M. K., Effect of Hemofiltration Filter Adsorption on Circulating IL-6 Levels in Sepsic Rats, Critical Care 2002, 6:429-433.	
	BC	Makin A.J. et al., System and hepatic hemodynamic changes in acute liver injury. Am. J. Physiol., 1997; 272:G617-G625.	
	BD	Morimoto T. et al., Plasma absorption using bilirubin-absorbent materials as a treatment for patients with hepatic failure, Artificial Organs 1989, 447-452.	
	BE	Mullen KD, Dasarathy S., Hepatic encephalopathy. ER Schiff et al. (eds), Schiff's Diseases of the Liver, 8 <sup>th</sup> edition, Lippincott-Raven Publishers, Philadelphia, 1999	
	BF	Nagaki M. et al., In vitro plasma perfusion through adsorbents and plasma ultrafiltration to remove endotoxin and cytokines, Circulatory Shock 1992; 38:182-8.	
	BG	Nagaki M. et al., Removal of endotoxin and cytokines by absorbent and the effect of plasma protein binding, Liver Unit, King's College School of Medicine and Dentistry 1991; 4:43-50.	
	BH	Nakae H, Yonekawa C, Wada H, Asanuma Y, Sato T, Tanaka H. Effectiveness of combining plasma exchange and continuous hemodiafiltration (combined modality therapy in a parallel circuit) in the treatment of patients with acute hepatic failure, Ther Apher., 2001;5:471-475.	
Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.4. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application or to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, Patent and Trademark Office, US Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

				Application Number	10/785,215
				Filing Date	02/23/2004
				First Named Inventor	Craig P. Roberts
				Group Art Unit	1614
				Examiner Name	Unassigned
Sheet	3	of	3	Attorney Docket Number	51283-00002

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BI	Odnopozov V.A. et al. Effect of hemocarboperfusion on organ blood flow and survival in procine endotoxic shock. Crit. Care Med., 1996; 24:2020-2026.	
	BJ	Peltekan KM, Levy GA : Role of cytokines and immune mechanisms in acute liver failure. In Acute Liver Failure. Edited by Lee WM et al. (eds.), Cambridge Press; 1997.	
	BK	Rahman T.M. and Hodgson H.J.. Review article: Liver Support Systems in Acute Hepatic Failure. Aliment. Pharmacol. Ther., 1999; 13: 1255-1272.	
	BL	Ronco C, Brendolan A, Lonnemann G, Bellomo R, Piccinni P, Digito A, Dan M, Irone M, La Greca G, Inguaggiato P, Maggiore U, De Nitti C, Wratten ML, Ricci Z, Tetta C., A pilot study of coupled plasma filtration with adsorption in septic shock, Crit Care Med 2002;30:1250-55.	
	BM	Ryan C.J. et al., Preclinical evaluation of haemosorbents, The Inter'l Journal of Artificial Organs 1986; 9-5:293-296.	
	BN	Ryan C.J. et al., Repeated membrane plasma separation with on-line sorbent treatment of plasma in the conscious rat, 1986; Artificial Organs, 10(2):135-144.	
	BO	Schiødt FV, Atillasoy E, Shakil AO, et al., Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg., 1999; 5:29-34.	
	BP	Schiødt FV, Rochling FA, Casey DL, Lee WM, Acetaminophen toxicity in an urban county hospital. N Engl J Med., 1997; 337:1112-1117.	
	BQ	Strange J. et al., Liver support by extracorporeal blood purification-A clinical observation, German Ministry for Research and Technology, Germany, 2000; 6(5):603-613.	
	BR	Sudan DL, Shaw BW Jr. Fox IJ, Langnas AN, Long-term follow up of auxiliary orthotopic liver transplantation for the treatment of fulminant hepatic failure. Surgery, 1997; 122(4):777-778.	
	BS	Sussman N.L., Chong M.G., Koussayer T. et al. Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology, 1992; 16: 60-65.	
	BT	Terblanche J. and Hickman R., Animal models of fulminant liver failure, Digest. Dis. Sci. 1991; 36:770-4.	
	BU	Tetta C. et al., Endotoxin and cytokine removal in sepsis, Ther. Apher 2002, 16:109-115	
	BV	Wedon J.A., Harrison P.M., Keays R., Williams R., Cerebral blood flow and metabolism in fulminant liver failure, Hepatology, 1994; 19: 1407-1413.	
	BW	Wehler M. et al., Short-term prognosis in critically ill patients with cirrhosis assessed by prognostic scoring systems, Hepatology, 2001; 34:255-261.	
	BX	Williams R., New directions in acute liver failure, J Royal College of Physicians of London, 1994; 28:552-559.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.4. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application or to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, Patent and Trademark Office, US Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.